Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Kroese, Tiuri Evan Hillegersberg, Richard
Schoppmann, Sebastian
Deseyne, Pieter R A J
Nafteux, Philippe
Obermannova, Radka
Nordsmark, Marianne
Pfeiffer, Per
Hawkins, Maria A
Smyth, Elizabeth
Markar, Sheraz
Hanna, George B
Cheong, Edward
Chaudry, Asif
Elme, Anneli
Adenis, Antoine
Piessen, Guillaume
Gani, Cihan
Bruns, Christiane J
Moehler, Markus
Liakakos, Theodore
Reynolds, John
Morganti, Alessio
Rosati, Riccardo
Castoro, Carlo
D'Ugo, Domenico
Roviello, Franco
Bencivenga, Maria
de Manzoni, Giovanni
Jeene, Paul
van Sandick, Johanna W
Muijs, Christel
Slingerland, Marije
Nieuwenhuijzen, Grard
Wijnhoven, Bas
Beerepoot, Laurens V
Kolodziejczyk, Piotr
Polkowski, Wojciech P
Alsina, Maria
Pera, Manuel
Kanonnikoff, Tania F
Nilsson, Magnus
Guckenberger, Matthias
Monig, Stefan
Wagner, Dorethea
Wyrwicz, Lucjan
Berbee, Maaike
Gockel, Ines
Lordick, Florian
Griffiths, Ewen A
Verheij, Marcel
van Rossum, Peter S N
van Laarhoven, Hanneke W M
Publication date
2022-02-05
Metadata
Show full item recordAbstract
Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%-75%), or consensus (≥75%). Results: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists.Citation
Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkins MA, Smyth E, Markar S, Hanna GB, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns CJ, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick JW, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot LV, Kolodziejczyk P, Polkowski WP, Alsina M, Pera M, Kanonnikoff TF, Nilsson M, Guckenberger M, Monig S, Wagner D, Wyrwicz L, Berbee M, Gockel I, Lordick F, Griffiths EA, Verheij M, van Rossum PSN, van Laarhoven HWM; OMEC working group. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer. 2022 Mar;164:18-29. doi: 10.1016/j.ejca.2021.11.032. Epub 2022 Feb 5Type
ArticleAdditional Links
https://www.sciencedirect.com/journal/european-journal-of-cancerPMID
35134666Journal
European Journal of CancerPublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2021.11.032